Category: MS Drug Therapies

Teva Comments on Anticipated At-Risk U.S. Launch of Generic Glatiramer Acetate 40mg/mL and Launch of Generic Glatiramer Acetate 20mg/mL

JERUSALEM–(BUSINESS WIRE)–Oct. 4, 2017– Teva Pharmaceutical Industries Ltd. today commented that any launch by Mylan of a generic version of COPAXONE® 40mg/ml…

Stuart Schlossman

Long-term Lemtrada Treatment Benefits Demonstrated in Extension Study

October 2, 2017 A five-year study demonstrated that Sanofi-Genzyme’s Lemtrada(alemtuzumab) provides long-term benefits for relapsing-remitting multiple sclerosis patients, reducing relapse rates and preventing…

Stuart Schlossman

RebiSmart Usage Among Young, Less Disabled MS Patients May Improve with More Knowledge, Study Suggests

Relapsing-remitting multiple sclerosis (RRMS) patients accurately report the use of the RebiSmart autoinjector to their neurologists, a questionnaire-based study has…

Stuart Schlossman

When to obtain an MRI, in a Lemtrada treated Person with MS

Stuart Schlossman

Promising New Treatments for Multiple Sclerosis

Stuart Schlossman

UCSF Neurologist Played Key Role in MS Research Turning to B-Cells, Essential Step to Ocrevus

Stuart Schlossman

Quarter of MS Patients in UK Not Aware of Disease-modifying Treatments, Online Survey Reports

Stuart Schlossman

Fighting in Court Over MS Generics

Stuart Schlossman

Mavenclad Reduces MS Relapses by Reseting the Immune System

Stuart Schlossman

Cladribine Tablets Are Only a Step Away from European Union Approval for Relapsing Multiple Sclerosis

Stuart Schlossman